

## CHUNG LEE LECTURESHIP

# Targeting Transcription Factor Neo-Enhancesomes in Cancer

**Tuesday, October 3, 2023**

11:00 a.m. – 12:00 p.m. Central Time

Baldwin Auditorium, 1st Floor  
Robert H. Lurie Medical Research Center  
303 E. Superior St., Chicago, IL

Dr. Chinnaiyan's group has characterized a number of important biomarkers of prostate cancer including AMACR, EZH2, the sarcosine metabolite, and most recently the long non-coding RNA (lncRNA) Schlap1. AMACR is being used clinically across the country in the assessment of cancer in prostate needle biopsies. His landmark study thus far is the discovery of TMPRSS2-ETS gene fusions in prostate cancer. TMPRSS2-ETS gene fusions are specific markers of prostate cancer as well as presumably function as rational targets for this disease.



## Arul Chinnaiyan, MD, PhD

Director, Michigan Center for Translational Pathology  
S.P. Hicks Endowed Professor of Pathology  
Investigator, Howard Hughes Medical Institute  
American Cancer Society Research Professor  
University of Michigan

Hosted by Maha Hussain, MD, Sarki Abdulkadir, MD, PhD, and Robin Leikin, PhD  
Supported by the Training Program in Signal Transduction and Cancer (T32CA070085)

**[cancer.northwestern.edu/education](https://cancer.northwestern.edu/education)**

Questions? [cancer@northwestern.edu](mailto:cancer@northwestern.edu)